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Breast cancer susceptibility variants frequently show heterogeneity in associations by 
tumor subtype. To identify novel loci, we performed a genome-wide association study 
(GWAS) including 133,384 breast cancer cases and 113,789 controls, plus 18,908 
BRCA1 mutation carriers (9,414 with breast cancer) of European ancestry, using both 
standard and novel methodologies that account for underlying tumor heterogeneity by 
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth 
factor receptor 2 (HER2) status and tumor grade. We identified 32 novel susceptibility 
loci (P<5.0x10-8), 15 of which showed evidence for associations with at least one tumor 
feature (false discovery rate <0.05). Five loci showed associations (P<0.05) in opposite 
directions between luminal- and non-luminal subtypes. In-silico analyses showed these 
five loci contained cell-specific enhancers that differed between normal luminal and 
basal mammary cells. The genetic correlations between five intrinsic-like subtypes 
ranged from 0.49 to 0.87. The proportion of heritability explained by all known 
susceptibility loci was 31.9% for triple-negative and 45.2% for luminal A-like disease. 
These findings provide improved understanding of genetic predisposition to breast 
cancer subtypes and will inform the development of subtype-specific polygenic risk 
scores.  
  
GWAS have identified over 170 independent breast cancer susceptibility loci, 
many of which show differential associations by tumor subtypes, particularly ER-positive 
versus ER-negative or triple negative (TN) disease1-3. However, prior GWAS have not 
simultaneously investigated multiple, correlated tumor markers to identify additional 
source(s) of etiologic heterogeneity. We performed a breast cancer GWAS using both 
standard analyses and a novel two-stage polytomous regression method that efficiently 
characterizes etiologic heterogeneity while accounting for tumor marker correlations and 
missing data4.  
The study populations and genotyping are described elsewhere1,2,5,6 and in the 
Online Methods. Briefly, we analyzed data from 118,474 cases and 96,201 controls of 
European ancestry participating in 82 studies from the Breast Cancer Association 
Consortium (BCAC) and 9,414 affected and 9,494 unaffected BRCA1 mutation carriers 
from 60 studies from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) 
with genotyping data from one of two Illumina genome-wide custom arrays. In analyses 
of overall breast cancer, we also included summary level data from 11 other breast 
cancer GWAS (14,910 cases and 17,588 controls) without subtype information. Our 
study expands upon previous BCAC GWAS1, with additional data on 10,407 cases and 
7,815 controls, an approximate increase of 10% and 9%, respecitvely. (Supplementary 
Tables 1-4). 
The statistical methods are further described in the Online Methods and in 
Supplementary Figure 1. To identify single nucleotide polymorphisms (SNPs) for 
overall breast cancer (invasive, in situ or unknown invasiveness) in BCAC, we used 
standard logistic regression to estimate odds ratios (OR) and 95% confidence-intervals 
(CI) adjusting for country and principal components (PCs). iCOGS and OncoArray data 
were evaluated separately and results combined with those from the 11 other GWAS 
using fixed-effects meta-analysis.  
To identify invasive breast cancer susceptibility SNPs displaying evidence of 
heterogeneity, we used a novel score-tests based on a two-stage polytomous model4 
that allows flexible, yet parsimonious, modelling of associations in the presence of 
underlying heterogeneity by ER, PR, HER2 and/or grade (Online Methods, 
Supplementary Note)7. The model handles missing tumor characteristic data by 
implementing an efficient Expectation-Maximization algorithm4,8. These analyses were 
restricted to BCAC controls and invasive cases (Online Methods). We fit an additional 
two-stage model to estimate case-control ORs and 95% CI between the SNPs and 
intrinsic-like subtypes defined by combinations of ER, PR, HER2 and grade (Online 
Methods): (1) luminal A-like, (2) luminal B/HER2-negative-like, (3) luminal B-like, (4) 
HER2-enriched-like and (5) TN or basal-like. We analyzed iCOGS and OncoArray data 
separately, adjusting for PCs and age, and meta-analyzed the results using a fixed-
effects model. We evaluated the effect of country using a leave-one-out sensitivity 
analysis (Online Methods). 
We used data from the BRCA1 mutation carriers who are prone to develop TN 
disease9, to estimate per-allele hazard ratios (HRs) within a retrospective cohort 
analysis framework. We assumed the estimated ORs for BCAC TN cases and the HRs 
estimated from CIMBA BRCA1 carriers approximated the same underlying relative risk9, 
and used a fixed-effect meta-analysis to combine these risk estimates (Online 
Methods). We used the two-stage polytomous model to test for heterogeneity in 
associations for all newly identified SNPs across subtypes, globally and by tumor-
specific markers (Online Methods). 
Overall, we identified 32 novel independent susceptibility loci marked by SNPs 
with P<5.0x10-8 (Figure 1, Supplementary Table 5-7, Supplementary Figure 2-6): 22 
SNPs using standard logistic regression, eight SNPs using the two-stage polytomous 
model and three SNPs in the CIMBA/BCAC-TN meta-analysis (rs78378222 was also 
detected by the two-stage polytomous model in BCAC). Fourteen additional significant 
(P<5.0x10-8) SNPs were excluded, 13 because they lacked evidence of association 
independent of previously reported susceptibility SNPs in conditional analyses (P 
≥1.0x10-6; Supplementary Table 8-10), and one (chr22:40042814) for showing a high-
degree of sensitivity to leave-one-out country analysis (Supplementary Figure 7). 
Supplemental figures 8-9 show the associations between all 32 SNPs and the 
intrinsic-like subtypes.  
Fifteen of the 32 SNPs showed evidence of heterogeneity (FDR<0.05) according 
to the global heterogeneity test (Figure 2, Supplementary Table 11). Nine of these 
were identified in analyses accounting for tumor marker heterogeneity. ER (7 SNPs) 
and grade (7 SNPs) most often contributed to observed heterogeneity (marker-specific 
P<0.05), followed by HER2 (4 SNPs) and PR (2 SNPs). rs17215231, identified in the 
CIMBA/BCAC-TN meta-analysis, was the only SNP found exclusively associated with 
TN disease (OR=0.85, 95%CI=0.81-0.89; P=8.6x10-13). rs2464195, also identified in the 
CIMBA/BCAC-TN meta-analysis, was associated with both TN (OR=0.93, 95%CI=0.91-
0.96; P=2.5x10-8) and luminal B-like subtypes (OR=0.96, 95%CI=0.92-0.99; P=0.02; 
Supplementary Table 7, Supplementary Figure 9). This SNP is in LD (r2=0.62) with 
rs7953249, which is differentially associated with risk of subtypes of ovarian cancer10. 
Five of these heterogeneous SNPs showed associations with luminal and non-luminal 
subtypes in opposite directions (Figure 3). For example, four SNPs were associated in 
opposite directions with luminal A-like and TN subtypes (respectively, for rs78378222 
OR=1.13, 95%CI=1.05-1.20 vs OR=0.67, 95%CI=0.57-0.80; for rs206435 OR=1.03, 
95%CI=1.01-1.05 vs OR=0.95, 95%CI=0.92-0.98; for rs141526427 OR=0.96, 
95%CI=0.94-0.98 vs OR=1.04, 95%CI=1.01-1.08; and for rs6065254 OR=0.96, 
95%CI=0.94-0.97 vs OR=1.04, 95%CI=1.01-1.07). The specific tumor-marker 
heterogeneity test showed rs78378222 associated with ER (PER=7.0x10-6) and HER2 
(PHER2=2.07x10-4), rs206435 associated with ER (PER=2.8x10-3) and grade 
(Pgrade=2.8x10-4) and rs141526427 (PER=1.3x10-3) and rs6065254 (PER=4.3x10-3) 
associated with ER. rs7924772 showed opposite associations between HER2-negative 
and HER2-positive subtypes (e.g., OR=1.04, 95%CI=1.03-1.06 for luminal A-like 
disease and OR=0.95, 95%CI=0.92-0.99 for luminal B-like disease) and, consistent with 
these findings, was exclusively associated with HER2 (PHER2=1.4x10-6; Figure 3). Notably, 
rs78378222 located in the 3’ UTR of TP53 also showed opposite associations with high-
grade serous cancers (OR=0.75, P=3.7x10-4) and low-grade serous cancers (OR=1.58, 
P=1.5x10-4; http://ocac.ccge.medschl.cam.ac.uk). Moreover, prior analyses did not find 
rs78378222 associated with risk of breast cancer, likely due to its opposite effects 
between subtypes11. 
 We defined a set of candidate causal variants (CCVs; Online Methods) for each 
novel locus and investigated the CCVs in relation to previously-annotated enhancers in 
primary breast cells12. Based on combinations of H3K4me1 and H3K27ac histone 
modification ChIP-seq signals, putative enhancers in basal cells (BC), luminal 
progenitor (LP) and mature luminal cells (LM) were characterized as “OFF,” “PRIMED”, 
and “ACTIVE” (Online Methods). We defined “ANYSWITCH” enhancers as those 
exhibiting different states between cell types. Among the five loci showing evidence of 
having associations in opposite directions between some subtypes, at least one CCV 
per locus overlapped an “ANYSWITCH” enhancer (Figure 4). For example, rs78378222 
overlapped an ACTIVE enhancer in BC, PRIMED in LP and OFF in LM. In comparison, 
63% of the loci with consistent direction of associations across subtypes overlapped 
with an “ANYSWITCH” enhancer (Supplementary Table 12-13). These results support 
the hypothesis that some variants may modulate enhancer activity in a cell-type specific 
manner and thus differentially influence the risk of developing different tumor subtypes. 
  We used INQUIST to intersect each of the CCVs with functional annotation data 
from public databases to identify potential target genes1 (Online Methods, 
Supplementary Table 14). We predicted 179 unique target genes for 26 of the 32 
independent signals. Twenty-three target genes in 14 regions were predicted with high 
confidence (designated “Level 1”), of which 22 target genes in 13 regions were 
predicted to be distally regulated. These targets include four genes predicted as 
INQUISIT targets in previous studies13,14 POLR3C, RNF115, SOX4 and TBX3, a known 
somatic breast cancer driver gene15, and genes implicated by transcriptome-wide 
association studies (LINC0088616 and YBEY17).  
 We used stratified LD-regression to investigate the genetic architecture of 
molecular subtypes by evaluating the genetic correlations18,19 between subtypes and 
comparing enrichment of genomic features20 between luminal A-like and TN subtypes 
(Online Methods). All intrinsic-like subtypes were moderately- to highly-correlated, with 
luminal B/HER2-negative-like and TN subtypes (r=0.49, SE=0.06), and luminal A-like 
and TN (r=0.50, SE=0.04; Figure 4; Supplementary Table 15) having the lowest 
genetic correlations. Breast cancer in BRCA1 mutation carriers and TN disease were 
highly genetically correlated (r=0.83, SE=0.08). To compare genomic enrichment, we 
first evaluated 53 annotations and found TN tumors were most enriched for “super-
enhancers, extend500bp” (3.04-fold, P= 3.3x10-6), and “digital genomic footprint, 
extend500bp” (from DNase hypersensitive sites) (2.2-fold, P=4.0x10-4) (Supplementary 
Table 16, Supplementary Figure 10). However, none of the 53 annotations 
significantly differed between luminal A-like and TN tumors. We also investigated cell-
specific enrichment of four histone markers - H3K4me1, H3K3me3, H3K9ac and 
H3K27ac (Online Methods) - and found enrichment in both luminal-A and TN subtypes 
for gastrointestinal cell types and suppression of central nervous system cell types 
(Supplementary Figure 11). 
The 32 identified SNPs explain approximately 1.2% of the two-fold familial 
relative risk for overall breast cancer. Collectively, the known and newly-identified 
common susceptibility SNPs explain approximately 18.3% of the familial relative risk. 
Moreover, we estimate that all common (MAF>0.01), reliably imputed variants on 
OncoArray can explain approximately 40.2% of the familial risk (Online Methods). The 
heritability explained by all identified susceptibility SNPs for the intrinsic-like subtypes 
ranged from 30.47% for HER2-enriched-like to 45.19% for luminal A-like, and for 
BRCA1 carriers the explained heritability was 23.43% (Table 1). These analyses 
demonstrate the benefit of combining standard GWAS methods with methods 
accounting for underlying tumor heterogeneity. Moreover, they may help clarify 
mechanisms predisposing to specific molecular subtypes, and provide precise risk 
estimates for molecular subtypes to inform the development of subtype-specific 
polygenic risk scores21.  
 
 
  
Online Methods 
 
Study populations 
The overall breast cancer analyses included women of European ancestry from 
82 BCAC studies from over 20 countries, with genotyping data derived from two Illumina 
genome-wide custom arrays, the iCOGS and OncoArray (Supplementary Table 1). 
Most of the studies were case-control studies in the general population, or hospital 
setting, or nested within population-based cohorts, but a subset of studies oversampled 
cases with a family history of the disease. We included controls and cases of invasive 
breast cancer, carcinoma in-situ, and cases of unknown invasiveness. Information on 
clinicopathologic characteristics were collected by the individual studies and combined 
in a central database after quality control checks. We used BCAC database version 
‘freeze’ 10 for these analyses. Among a subset of participants (n=16,766) that were 
genotyped on both the iCOGS and OncoArray arrays, we kept only the OncoArray data. 
One study (LMBC) contributing to the iCOGS dataset was excluded due to inflation of 
the test statistics that was not corrected by adjustment for the first ten PCs. We also 
excluded OncoArray data from Norway (the Norwegian Breast Cancer Study) because 
there were no controls available from Norway with OncoArray data. All participating 
studies were approved by their appropriate ethics or institutional review board and all 
participants provided informed consent. The total sample size for this analysis, including 
iCOGS, OncoArray and other GWAS data, comprised 133,384 cases and 113,789 
controls.  
In the GWAS analyses accounting for underlying heterogeneity according to ER, 
PR, HER2 and grade, we included genotyping data from 81 BCAC studies. These 
analyses were restricted to controls and cases of invasive breast cancer; we excluded 
cases of carcinoma in-situ and cases with missing information on invasiveness, as 
these cases would potentially bias the implicit “imputation” of tumor marker in the 
underlying EM algorithm (Supplemental Table 2). We also excluded all studies from a 
specific country if there were no controls for that country, or if the tumor marker data 
were missing on two or more of the tumor marker subtypes (see footnote of 
Supplemental Table 2 for further explanation of excluded studies). We did not include 
the summary results from the 14,910 cases and 17,588 controls from the 11 other 
GWAS in subtype analyses because these studies did not provide data on tumor 
characteristics. We also excluded invasive cases (n=293) and controls (n=4,285) with 
missing data on age at diagnosis or age at enrollment, information required by the EM 
algorithm to impute missing tumor characteristics. In total, the final sample for the two-
stage polytomous logistic regression comprised 106,278 invasive cases and 91,477 
controls. 
Participants included from CIMBA were women of European ancestry, aged 18 
years or older with a pathogenic BRCA1 variant. Most participants were sampled 
through cancer genetics clinics. In some instances, multiple members of the same 
family were enrolled. OncoArray genotype data was available from 58 studies from 24 
countries. Following quality control and removal of participants that overlapped with the 
BCAC OncoArray study, data were available on 15,566 BRCA1 mutation carriers, of 
whom 7,784 were affected with breast cancer (Supplementary Table 3). We also 
obtained iCOGS genotype data on 3,342 BRCA1 mutation carriers (1,630 with breast 
cancer) from 54 studies through CIMBA. All BRCA1 mutation carriers provided written 
informed consent and participated under ethically approved protocols. 
 
Genotyping, quality control, and imputation 
Details on genotype calling, quality control and imputation for the OncoArray, 
iCOGS, and GWAS are described elsewhere1,2,5,6. Genotyped or imputed SNPs 
marking each of the loci were determined using the iCOGS and the OncoArray 
genotyping arrays and imputation to the 1000 Genomes Project (Phase 3) reference 
panel. We included SNPs, from each component GWAS with an imputation quality 
score of >0.3. We restricted analysis to SNPs with a minor allele frequency >0.005 in 
the overall breast cancer analysis and >0.01 in the subtype analysis. 
 
Known breast cancer susceptibility variants  
Prior studies identified susceptibility SNPs from genome-wide analyses at a 
significance level P< 5.0×10−8 for all breast cancer types, ER-negative or ER-positive 
breast cancer, in BRCA1 or BRCA2 mutation carriers, or in meta-analyses of these1,2. 
We defined known breast cancer susceptibility variants as those variants that were 
identified or replicated in prior BCAC analyses1,2. We also excluded from consideration 
variants within 500kb of a previously published locus, since these regions have been 
subject to separate conditional analyses14. 
 
Standard analysis of BCAC data: Logistic regression analyses were conducted 
separately for the iCOGS and OncoArray datasets, adjusting for country and the array-
specific first 10 PCs for ancestry informative SNPs. The methods for estimating PCs 
have been described elsewhere1,2. For the remaining GWAS, adjustment for inflation 
was done by adjusting for up to three PCs and using genomic control adjustment, as 
previously described1. We evaluated the associations between approximately 10.8 
million SNPs with imputation quality scores (r2) ≥0.3 and MAF >0.005. We excluded 
SNPs located within ±500 KB of, or in LD (r2≥0.1) with known susceptibility SNPs22. 
The association effect size estimates from these, and the previously derived estimates 
from the 11 other GWAS, were then combined using a fixed effects meta-analysis. 
Since individual level genotyping data were not available for some previous GWAS, we 
conservatively approximated the potential overlap between the GWAS and iCOGS and 
OncoArray datasets, based on the populations contributing to each GWAS 
(iCOGS/GWAS: 626 controls and 923 cases; OncoArray/GWAS: 20 controls and 990 
cases). We then used these adjusted data to estimate the correlation in the effect size 
estimates, and incorporated these into the meta-analysis using the method of Lin and 
Sullivan23. 
 
Subtypes analysis of BCAC data: We described the two-stage polytomous logistic 
regression in more detail elsewhere4,24 (Supplementary Note). In brief, this method 
allows for efficient testing of a SNP-disease association in the presence of tumor 
subtype heterogeneity defined by multiple tumor characteristics, while accounting for 
multiple testing and missing data on tumor characteristics. In the first stage, the model 
uses a polytomous logistic regression to model case-control ORs between the SNPs 
and all possible subtypes that could be of interest, defined by the combination of the 
tumor markers. For example, in a model fit to evaluate heterogeneity according to ER, 
PR and HER2 positive/negative status, and grade of differentiation (low, intermediate 
and high grade), the first stage incorporates case-control ORs for 24 subtypes defined 
by the cross-classification of these factors. The second stage restructures the first-stage 
subtype-specific case-control ORs parameters into second-stage parameters through a 
decomposition procedure resulting in a second-stage baseline parameter that 
represents a case-control OR of a baseline cancer subtype, and case-case ORs 
parameters for each individual tumor characteristic. The second-stage case-case 
parameters can be used to perform heterogeneity tests with respect to each specific 
tumor marker while adjusting for the other tumor markers in the model. The two-stage 
model efficiently handles missing data by implementing an Expectation-Maximization 
algorithm4,8 that essentially performs iterative “imputation” of the missing tumor 
characteristics conditional on available tumor characteristics and baseline covariates 
based on an underlying two-stage polytomous model. 
To identify novel susceptibility loci, we used both a fixed-effect two-stage 
polytomous model and a mixed-effect two-stage polytomous model. The score-test we 
developed based on the mixed-effect model allows coefficients associated with 
individual tumor characteristics to enter as either fixed- or random-effect terms. Our 
previous analyses have shown that incorporation of random effect terms can improve 
power of the score-test by essentially reducing the effective degrees-of-freedom 
associated with fixed effects related to exploratory markers (i.e., markers for which there 
is little prior evidence to suggest that they are a source of heterogeneity)25. On the other 
hand, incorporation of fixed-effect terms can preserve distinct associations of known 
important tumor characteristics, such as ER. In the mixed-effect two-stage polytomous 
model, we therefore kept ER as a fixed effect, but modeled PR, HER2 and grade as 
random effects. We evaluated SNPs with MAF >0.01 (~9.7 million) and r2≥0.3, and 
excluded SNPs within ±500 kb of, or in LD (r2≥0.1) with known susceptibility SNPs, 
including those identified in the standard analysis for overall breast cancer. We reported 
SNPs that passed the p-value threshold of P < 5.0x10-8 in either the fixed- or mixed-
effects models. 
We assessed the influence of country on signals identified by the two-stage 
models by performing a ‘leave one out’ sensitivity analyses in which we reevaluated 
novel signals after excluding data from each individual country. Data from the 
OncoArray and iCOGS arrays were analyzed separately and then meta-analyzed using 
fixed-effects meta-analysis.  
Statistical analysis of CIMBA data: We tested for associations between SNPs 
and breast cancer risk for BRCA1 mutation carriers using a score test statistic based on 
the retrospective likelihood of observing the SNP genotypes conditional on breast 
cancer phenotypes (breast cancer status and censoring time)26. Analyses were 
performed separately for iCOGS and OncoArray data. To allow for non-independence 
among related individuals, a kinship-adjusted test was used that accounted for familial 
correlations27. We stratified analyses by country of residence and, for countries where 
the strata were sufficiently large (United States and Canada), by Ashkenazi Jewish 
ancestry. The results from the iCOGS and OncoArray data were then pooled using 
fixed-effects meta-analysis.  
Meta-analysis of BCAC and CIMBA: We performed a fixed-effects meta-
analysis of the results from BCAC TN cases and CIMBA BRCA1 mutation carriers, 
using an inverse-variance fixed-effects approach implemented in METAL28. The 
estimates of association used were the logarithm of the per-allele hazard ratio estimate 
for association with breast cancer risk for BRCA1 mutation carriers from CIMBA and the 
logarithm of the per-allele odds ratio estimate for association with risk of TN breast 
cancer based on BCAC data.  
Conditional analyses: We performed two sets of conditional analyses. First, we 
investigated for evidence of multiple independent signals in identified loci by performing 
forward selection logistic regression, in which we adjusted the lead SNP and analyzed 
association for all remaining SNPs within ±500 kb of the lead SNPs, irrespective of LD. 
Second, we confirmed the independence of 20 SNPs that were located within ±2 MB of 
a known susceptibility region by conditioning the identified signals on the nearby known 
signal. Since these 20 SNPs are already genome-wide significant in the original GWAS 
scan and the conditional analyses restricted to local regions, we therefore used a 
significance threshold of P<1x10-6 to control for type-one error29.  
Heterogeneity analysis of new association signals: We evaluated all novel 
signals for evidence of heterogeneity using two-stage polytomous model. We first 
performed a global test for heterogeneity under the mixed-effect model test to identify 
SNPs showing evidence of heterogeneity with respect to any of the underlying tumor 
markers, ER, PR, HER2 and/or grade. We accounted for multiple testing of the global 
heterogeneity test using a FDR <0.05 under the Benjamini-Hochberg procedure30. 
Among the SNPs with observed heterogeneity, we then further used a fixed-effect two-
stage model to evaluate influence of specific tumor characteristic(s) driving observed 
heterogeneity, adjusted for the other markers in the model. We also fit a separate fixed-
effect two-stage models to estimate case-control ORs and 95% confidence intervals 
(CI) for five surrogate intrinsic-like subtypes defined by combinations of ER, PR, HER2 
and grade31: (1) luminal A-like (ER+ and/or PR+, HER2-, grade 1 & 2); (2) luminal 
B,HER2-negative-like (ER+ and/or PR+, HER2-, grade 3); (3) luminal B-like (ER+ 
and/or PR+, HER2+); (4) HER2-enriched-like (ER- and PR-, HER2+), and (5) TN (ER-, 
PR-, HER2-). 
 
Effective sample size of cases of two-stage polytomous model 
The two-stage polytomous model implements the EM algorithm to impute 
missing tumor characteristics; therefore, the effective sample size of cases is not 
equivalent to the actual number of cases with available tumor characteristic data. We 
estimated the effective sample sizes to help demonstrate the benefit of using the EM 
algorithm to impute missing tumor characteristics and to aid comparability with previous 
studies (Supplementary Table 4). To estimate the effective sample size, suppose we 
have a complete dataset with no missing tumor characteristics, the sample size is n  for 
the kth subtype and n  for the control. If we fit a two-stage polytomous model for the jth 
SNP, the corresponding log odds ratio for kth subtype is 𝛽  and the standard error is 
s . Then, approximately: 
𝑣𝑎𝑟 𝛽 𝑝 =
𝑛 + 𝑛
2 ∗ 𝑝 1 − 𝑝 (𝑛 𝑛 )
, 
where p  is the MAF of the jth SNP. Now we consider fitting a two-stage polytomous 
model with missing tumor characteristics. Given the standard error s  of the log odds 
ratio and the control sample size, we have the estimate of effective number of cases as, 
𝑛 = − 2𝑠 𝑝 (1 − 𝑝 ) . 
We used the median estimates of effective sample size of cases for all SNPs as the 
final estimate.  
 
Candidate causal variants 
We defined credible sets of candidate causal variants (CCVs) as variants located 
within ±500kb of the lead SNPs in each novel region and with P values within 100-fold 
of magnitude of the lead SNPs. This is approximately equivalent to selecting variants 
whose posterior probability of causality is within two orders of magnitude of the most 
significant SNP32,33. This approach was applied for detecting a set of potentially causal 
variants for all 32 identified SNPs. For the novel SNPs located within ±2Mb of the 
known signals, we used the conditional P values to adjust for the known signals’ 
associations.  
 
eQTL Analysis 
Data from breast cancer tumors and adjacent normal breast tissue were 
accessed from The Cancer Genome Atlas (TCGA)34. Germline SNP genotypes 
(Affymetrix 6.0 arrays) were processed and imputed to the 1000 Genomes reference 
panel (October 2014) and European ancestry ascertained as previously described1. 
Tumor tissue copy number was estimated from the Affymetrix 6.0 and called using the 
GISTIC2 algorithm35. Complete genotype, RNA-seq and copy number data were 
available for 679 genetically European patients (78 with adjacent normal tissue). 
Further, RNA-seq for normal breast tissue and imputed germline genotype data were 
available from 80 females from the GTEx Consortium36. Genes with a median 
expression level of 0 RPKM across samples were removed, and RPKM values of each 
gene were log2 transformed. Expression values of samples were quantile normalized. 
Genetic variants were evaluated for association with the expression of genes located 
within ±2Mb of the lead variant at each risk region using linear regression models, 
adjusting for ESR1 expression. Tumor tissue was also adjusted for copy number 
variation, as previously described37. eQTL analyses were performed using the 
MatrixEQTL program in R38. 
 
INQUISIT target gene analysis 
 Logic underlying INQUISIT predictions: Details of the INQUISIT pipeline have 
been previously described1. Briefly, genes were evaluated as potential targets of 
candidate causal variants through effects on: (1) distal gene regulation, (2) proximal 
regulation, or (3) a gene's coding sequence. We intersected CCV positions with multiple 
sources of genomic information, chromatin interaction analysis by paired-end tag 
sequencing (ChIA-PET)39 in MCF7 cells, and genome-wide chromosome conformation 
capture (Hi-C) in HMECs40. We used breast cell line computational enhancer–promoter 
correlations (PreSTIGE41, IM-PET42, FANTOM543) breast cell super-enhancer44, breast 
tissue-specific expression variants (eQTL) from multiple independent studies (TCGA 
(normal breast and breast tumor) and GTEx breast, See eQTL Methods), transcription 
factor and histone modification chromatin immunoprecipitation followed by sequencing 
(ChIP-seq) from the ENCODE and Roadmap Epigenomics Projects together with the 
genomic features found to be significantly enriched for all known breast cancer CCVs14, 
gene expression RNA-seq from several breast cancer lines and normal samples 
(ENCODE) and topologically associated domain (TAD) boundaries from T47D cells 
(ENCODE45). To assess the impact of intragenic variants, we evaluated their potential 
to alter primary protein coding sequence and splicing using Ensembl Variant Effect 
Predictor46 using MaxEntScan and dbscSNV modules for splicing alterations based on 
“ada” and “rf” scores. Nonsense and missense changes were assessed with the REVEL 
ensemble algorithm, with CCVs displaying REVEL scores > 0.5 deemed deleterious.  
Scoring hierarchy: Each target gene prediction category (distal, promoter or 
coding) was scored according to different criteria. Genes predicted to be distally-
regulated targets of CCVs were awarded two points based on physical links (for 
example ChIA-PET), and one point for computational prediction methods, or eQTL 
associations. All CCVs were considered as potentially involved in distal regulation and 
all CCVs (including coding SNPs) were scored in this category. Intersection of a 
putative distal enhancer with genomic features found to be significantly enriched20 were 
further upweighted with an additional point. In the case of multiple, independent 
interactions, an additional point was awarded. CCVs in gene proximal regulatory 
regions were intersected with histone ChIP-Seq peaks characteristic of promoters and 
assigned to the overlapping transcription start sites (defined as -1.0 kb - +0.1 kb). 
Further points were awarded to such genes if there was evidence for an eQTL 
association, while a lack of expression resulted in down-weighting as potential targets. 
Potential coding changes including missense, nonsense and predicted splicing 
alterations resulted in addition of one point to the encoded gene for each type of 
change, while lack of expression reduced the score. We added an additional point for 
predicted target genes that were also breast cancer drivers (278 genes1,20). For each 
category, scores potentially ranged from 0-8 (distal); 0-4 (promoter) or 0-3 (coding). We 
converted these scores into 'confidence levels': Level 1 (highest confidence) when distal 
score >4, promoter score  ≥3 or coding score >1; Level 2 when distal score  ≤4 and ≥1, 
promoter score=1 or=2, coding score=1; and Level 3 when distal score <1 and >0, 
promoter score <1 and >0, and coding <1 and >0. For genes with multiple scores (for 
example, predicted as targets from multiple independent risk signals or predicted to be 
impacted in several categories), we recorded the highest score.   
Enhancer states analysis in breast sub-populations 
We obtained enhancer maps for three enriched primary breast sub-populations 
(basal, luminal progenitor, and mature luminal) from Pellacani et al.12. Enhancer 
annotations were defined as ACTIVE, PRIMED, or OFF based on a combination of 
H3K27ac and H3K4me1 histone modification ChIP-seq signals using FPKM thresholds 
as previously described12. Briefly, genomic regions containing high H3K4me1 signal 
observed in any cell type were used to define the superset of breast regulatory 
elements. Sub-population cell type-specific H3K27ac signal (which is characteristic of 
active elements) within these elements was used as a measure of overall regulatory 
activity, where "ACTIVE" sites were characterized by H3K4me1-high, H3K27ac-high; 
"PRIMED" by H3K4me1-high, H3K27ac-low; and "OFF" by H3K4me1-low, H3K27ac-
low. This enabled annotation of each enhancer element as either “OFF”, “PRIMED” or 
“ACTIVE” in all cell types. We then defined enhancers which exhibit differing states 
between at least one cell type as "ANYSWITCH" enhancers.  
 
Genetic correlation analyses 
We used LD score regression18-20 to assess the heritability due to susceptibility 
SNPs and estimated the genetic correlation between five intrinsic-like breast cancer 
subtypes. The analysis used the summary statistics based on the meta-analysis of the 
OncoArray, and iCOGS, and CIMBA meta-analysis. The genetic correlation18 analysis 
was restricted to the ~1 million SNPs included in HapMap 3. Since two-stage 
polytomous models integrated an imputation algorithm for missing tumor characteristic 
data, we modified the LD score regression to generate the effective sample size for 
each SNP (Supplementary Note). 
 
Global genomic enrichment analyses 
We performed stratified LD score regression analyses20 as previously described1 
for two major intrinsic-like subtypes, luminal A-like and TN, using the summary statistics 
from the meta-analyses of OncoArray, iCOGs, and CIMBA. The analysis included all 
SNPs in the 1000 Genome Project Phase 1v3 release with MAF>1% and imputation 
quality score R2>0.3 in the OncoArray data. We first fit a model that included 24 non-
cell-type-specific, publicly available annotations as well as 24 additional annotations that 
included a 500-bp window around each of the 24 main annotations. We also included 
100-bp windows around ChIP–seq peaks and one annotation containing all SNPs, 
leading to a total of 53 overlapping annotations. In addition to the baseline model using 
24 main annotations, we also performed cell-type-specific analyses using annotations of 
the four histone marks (H3K4me1, H3K4me3, H3K9ac and H3K27ac). Each cell-type-
specific annotation corresponds to a histone mark in a single cell type (for example, 
H3K27ac in adipose nuclei tissues)20. There was a total of 220 such annotations. We 
further subdivided these 220 cell-type-specific annotations into 10 categories by 
aggregating the cell-type-specific annotations within each group (for example, SNPs 
related with any of the four histone modifications in any hematopoietic and immune cells 
were considered as one category). To estimate the enrichment of each marker, we ran 
220 LD score regressions after adding each different histone mark to the baseline 
model. We used a Wald test to evaluate the differences in the functional enrichment 
between the luminal A-like and TN subtypes, using the regression coefficients and 
standard error based on the models above. After Bonferroni correction none of the 
differences were significant. Notably, the Wald test assumes that the enrichment 
estimates of luminal A-like and TN subtypes were independent, but this assumption was 
violated by the sharing of controls between the subtypes. Under this scenario, our Wald 
test statistics were less conservative than had we adjusted for the correlation between 
estimates. However, given the lack of significant differences observed between luminal 
A-like and TN subtypes we had no concern about a type one error. 
 
Contribution of identified variants to the familial relative risk of breast cancer 
We define the familial relative risk as λ. Under a log-additive model, we define 
the heritability as σ , and the relationship between λ and σ  as σ = 2 ∗ log (𝜆) 47. Under 
the log-additive model, the frailty-scale heritability that is explained by the identified 
variants can be estimated by: 
2𝑝 (1 − 𝑝 )(𝛽 − 𝜏 ), 
where n is the total number of identified SNPs, p  is the MAF for variant I, 𝛽  is the log 
odds ratio estimate for the variant I, and τ  is the standard error of 𝛽 . The corresponding 
frailty-scale heritability for all variants is and σ  = 2 ∗ log (𝜆), where λ is the familial 
relative risk to first degree relatives of affected individuals, assuming a polygenic log-
additive model that explains all the familial aggregation of the disease47. We assumed 
λ = 2 as the overall familial relative risk of breast cancer, so the proportion of the familial 
relative risk explained by the identified SNPs is ∑ 𝑝 (1 − 𝑝 )(𝛽 − 𝜏 ) log (2)⁄ . To 
obtain the heritability explained by all of the GWAS variants, we estimated the 
heritability (σ ) using the full set of summary statistics using LD score regression as 
previously described1. σ  is characterized by population variance of the underlying 
true polygenetic risk scores as ℎ = 𝑉𝑎𝑟(∑ 𝛽 𝐺 ), where 𝛽  is the true log odds 
ratio for the 𝑚th SNP. The proportion of the familial relative risk explained by GWAS 
variants is σ  [2 ∗ log(2)]⁄ . Thus, the proportion of heritability explained by identified 
variants relative to all imputable SNPs is: 
∑ 2𝑝 (1 − 𝑝 )(𝛽 − 𝜏 ) /σ . 
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Figure 1. Manhattan plots showing 32 independent susceptibility loci crossing genome-wide significant 
threshold for associations with breast cancer risk A.) Twenty-two loci  (Supplementary Table 6) were 
identified from standard logistic regression analysis using 133,384 breast cancer cases and 113,789 
controls from BCAC; B.) eight loci (Supplementary Table 7) identified from two-stage polytomous 
regression using 106,278 invasive cases and 91,477 controls from BCAC; C.) three loci (Supplementary 
Table 8) were identified from meta-analysis of triple negative in BCAC and 18,908 female 
BRCA1(unaffected BRCA1 mutation carriers = 9,494). SNP rs78378222 was also detected in two-stage 
polytomous regression model.  
 
A.) Overall analysis identified 22 independent loci
B.) Two-stage polytomous regression identified 8 independent loci
C.) BCAC TN and CIMBA BRCA1 meta analysis identified 3 independent loci
Chromosome
Figure 2. Heatmap and clustering of p-values from marker specific heterogeneity test for 32 breast 
cancer susceptibility loci. P-values are for associations between the most significant SNPs marking each 
loci and estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 
(HER2) or grade, adjusting for top ten principal components and age. Fifteen SNPs in red color were 
significant according to the global heterogeneity tests (FDR <0.05) that evaluates if a SNP’s risk 
estimates vary by at least one of the four tumor characteristics.  
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Figure 3. Susceptibility SNPs with associations in opposite direction across subtypes. The case-control odds ratios (OR) and 95% confidence intervals (95% CI)1 
(left panel) are for associations of each of the five SNPs and risk for breast cancer intrinsic-like subtypes2 estimated from the first-stage of the two-stage 
polytomous regression fixed-effects model. The case-case ORs 95%CI (right panel) are estimated from the second stage parameters of a fixed effect two-stage 
polytomous models testing for heterogeneity between the five SNPs and estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 
receptor 2 (HER2) and grade, where ER, PR, HER2, and grade are mutually adjusted for each other. 
 
Case-control OR and 95% CI SNP chromosome Position Case-case OR and 95% CI MAF 
1 Per-minor allele odds ratio and 95% confidence limits 
2 luminal A-like (ER+ and/or PR+, HER2-, grade 1 & 2); luminal B/HER2-negative-like (ER+ and/or PR+, HER2-, grade 3); luminal B-like (ER+ and/or PR+, HER2+); (4) HER2-enriched-like (ER- and PR-, HER2+), and 
triple-negative (ER-, PR-, HER2-) 
         Luminal A-like              Luminal B/HER2-negative-like 
         Luminal B-like              HER2-enriched-like 
         ER            PR             HER2             grade 
Figure 4. Heatmap of candidate causal variants (CCVs) overlapping results with enhancer states in 
primary breast subpopulations for five SNPs with associations in opposite direction across subtypes. 
Three different breast subpopulations were considered: basal cells (BC), luminal progenitor (LP) and 
luminal cells mature (LM). Based on a combination of H3K4me1 and H3K27ac histone modification ChiP-
seq signals, putative enhancers in BC, LP, and LM were characterized as “OFF”, “PRIMED” and “ACTIVE” 
(Online Methods). The CCVs overlapping with enhancers were colored as red, otherwise were white. 
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Figure 5. Genetic correlation between the five intrinsic-like breast cancer subtypes and BRCA1 mutation 
carriers estimated through LD score regression. See Supplementary Table 14 for further details. 
 
  
Table 1. Subtypes heritability table under the frailty-scale1 
Phenotype 
Heritability for 
all identified 
susceptibility SNPs2 
Heritability for 
newly identified SNPs 
Heritability (SE) for 
all GWAS variants3 
Proportion explained 
by identified 
susceptibility loci4 
Luminal A-like 0.336 0.022 0.744 (0.082) 45.19% 
Luminal B/HER2-negative-like 0.233 0.018 0.693 (0.087) 33.59% 
Luminal B-like 0.270 0.020 0.797 (0.114) 33.84% 
HER2-enriched-like 0.200 0.011 0.657 (0.176) 30.47% 
Triple negative 0.185 0.025 0.580 (0.090) 31.90% 
CIMBA BRCA1 carriers 0.083 0.016 0.355 (0.088) 23.43% 
 
 
1 Due to a lack of information on the familial relative risk for breast cancer subtypes, we report the heritability under frailty-scale, which assumes the log 
additive model as the underlying model (Online Methods). 
2 Susceptibility SNPs included 178 SNPs identified or replicated in Nature 551, 92-94 (2017) and Nat Genet 49, 1767-1778 (2017) and 32 newly identified 
SNPs in this paper. 
3 Heritability of all GWAS variants was estimated through LD-score regression described in Nat Genet 47, 291-5 (2015). and Nat Genet 47, 1236-41 (2015). 
Under the frailty-scale, this heritability is characterized by population variance of the underlying true polygenic risk score as ℎ = 𝑉𝑎𝑟(∑ 𝛽 𝐺 ), where  
𝛽 𝑚th
